People Living with Systemic Lupus Erythematosus Demonstrate Clinically Meaningful Improvement with Cenerimod

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE). The drug’s multifaceted immunomodulatory properties target key aspects of SLE pathogenesis.

In the study, adults aged 18-75 years old with moderate-to-severe SLE were examined and monitored for a period of 12 months. From the 810 patients screened, 427 were randomly allocated to receive either once-daily oral cenerimod at doses of 0.5 mg, 1 mg, 2 mg, or 4 mg.  The remaining participants received the placebo, alongside their stable background SLE therapy. Cenerimod 4 mg showed significant and lasting improvements from baseline across various measures of SLE disease activity compared to placebo, when used alongside stable background SLE therapy. The treatment was well tolerated, with an adverse event profile that indicated no unexpected or unusual side effects. The results of this study informed the design and dose selection of the ongoing Phase 3 OPUS study.

The Phase 2b CARE study results were published in two prominent journals. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.

Read the annoucement